Related Experiment Video
Updated: May 2, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay
Published on: June 6, 2025
Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis
Radu Tanasescu1, Cris S Constantinescu
1University of Nottingham, Queen's Medical Centre, Academic Division of Clinical Neurology , C Floor, South Block, Nottingham, NG7 2UH , UK +44 115 8754597/98 ; +44 115 823 1443 ; cris.constantinescu@nottingham.ac.uk.
Introduction:
Fingolimod is a sphingosine 1-phosphate receptor modulator with a novel mechanism of action and the first oral drug approved for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod reduces relapses more effectively than intramuscular interferon β1a and delays disability progression. Associated safety risks are bradyarrhythmia and atrioventricular block following the initial dose, requiring monitoring.
Areas Covered:
This article examines the characteristics of fingolimod, its pharmacokinetic properties and the efficacy and tolerability in MS. Information on the pharmacology and mechanisms of action is also provided.
Expert Opinion:
Fingolimod is an effective therapy for relapsing forms of MS in a convenient oral dose. Fingolimod may target not only inflammation but potentially also neurodegeneration. Antagonizing astrocyte sphingosine signaling may help explain the reduction in cerebral atrophy observed in Phase III trials. Long-term data about the safety of fingolimod are needed.
More Related Videos
12:27A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
08:40Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Measurement of Bioavailability: Pharmacodynamic Methods
Bioavailability Study Design: Single Versus Multiple Dose Studies
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dosage Regimens: Partial Pharmacokinetic Parameters